Street stays bullish on Sun Pharma despite mixed Q2, earnings downgrades
NiveshIQ
NSE: SUNPHARMA · Healthcare
Sun Pharmaceutical Industries Ltd.
₹1,770.00▼ ₹7.70 (-0.43%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on SUNPHARMA. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Limited is a leading generic pharmaceutical company that designs, manufactures, and markets branded and generic formulations and APIs across India, the United States, and other international markets. The company’s revenue drivers include a diversified portfolio spanning neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, ophthalmology, oncology, and specialty drugs such as antiretrovirals and biologics. In 2023, Sun Pharma reported revenue of ₹59,911 crore and net income of ₹12,096 crore, reflecting a 10% YoY growth in sales and a 12% increase in operating margin. Recent developments include FDA approval of ILUMYA for psoriatic arthritis, expanding its biologics pipeline, and a temporary production halt of an eye-care drug in India due to
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹48,497 Cr +10.51% | ₹52,578 Cr +8.42% | ₹58,462 Cr +11.19% |
| EBITDA Margin | 26.85% | 29.05% | 30.33% |
| Net Profit | ₹9,576 Cr +13.01% | ₹10,929 Cr +14.12% | ₹11,479 Cr +5.04% |
| EPS | ₹39.90 | ₹45.60 | ₹47.80 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Sun Pharma shares fall 3% after Q2 profit plunges 36%; brokerages bullish but slash target prices
Sun Pharma slides nearly 2% as Ilumya concerns weigh on analyst estimates
🔒
+ 3 more stories about Sun Pharmaceutical Industries Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q2FY27 results: revenue ₹16, 199 Cr, PAT ₹1, 989 Cr, EPS ₹8.30, EBITDA margin 29.3%. Growth context: revenue YoY +11.9%, PAT YoY -36.2%, revenue QoQ +5.9%, PAT QoQ -31.3%.
Management commentary points to product launches, approvals, and therapy-mix improvement and new capacity addition and c...
FY26 (last completed FY): revenue ₹58, 462 Cr, PAT ₹11, 479 Cr, EBITDA margin 30.3%, EPS ₹47.80. Year-on-year: revenue Y...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Sai Life Sciences Ltd.Sanofi India Ltd.Senores Pharmaceuticals Ltd.Shilpa Medicare Ltd.Strides Pharma Science Ltd.Sun Pharma Advanced Research Company Ltd.Supriya Lifescience Ltd.Suven Life Sciences Ltd.Syngene International Ltd.Thyrocare Technologies Ltd.Torrent Pharmaceuticals Ltd.Ventive Hospitality Ltd.
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for SUNPHARMA
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track SUNPHARMA alongside your other holdings
Unlock full SUNPHARMA research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Sun Pharmaceutical Industries Ltd.?
NiveshIQ detects active intelligence signals for Sun Pharmaceutical Industries Ltd. (SUNPHARMA) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Sun Pharmaceutical Industries Ltd.?
Sun Pharmaceutical Industries Ltd. operates in the Healthcare sector with a market capitalisation of ₹47,122,937.3L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.